ANRO

Alto Neuroscience, Inc. NYSE Listed Feb 2, 2024

Healthcare ·Biotechnology ·US · altoneuroscience.com

$24.03

Mkt Cap $767.7M

52w Low $2.15 83.2% of range 52w High $28.44

50d MA $22.90 200d MA $13.64

P/E (TTM) -11.4x

EV/EBITDA -5.2x

P/B 4.8x

Debt/Equity 0.0x

ROE -41.8%

P/FCF -9.9x

RSI (14) —

ATR (14) —

Beta 2.06

50d MA $22.90

200d MA $13.64

Avg Volume 293.7K

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company that engages in the psychiatry drug development business. The company develops ALTO-100 for the treatment of patients with major depressive disorder (MDD) and post-traumatic stress disorder; ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties to treat patients with MDD; and ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor for the treatment of cognitive impairment associated with schizophrenia. It also develops ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist to treat patients with MDD and higher levels of anhedonia, and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor for the treatment of MDD. In addition, the company develops novel pharmacodynamically synergistic combinations and an AI-enabled biomarker platform that combine sources of information on patients brain activity and behavior to identify patients to respond to novel product candidates. Alto Neuroscience, Inc. was incorporated in 2019 and is based in Los Altos, California.

SIC Code

2834

CIK (SEC)

1999480

Phone

(650) 200-0412

369 South San Antonio Road · Mountain View, CA 94022 · US

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
May 13, 2026	TNS	-0.56	-0.80	-42.9%	22.85	-3.7%	+3.2%	—	—	—	—	—
Mar 16, 2026	TNS	-0.56	-0.45	+19.6%	24.29	+0.1%	-7.9%	+0.7%	-2.1%	-2.6%	-6.8%	—
Nov 12, 2025	TNS	-0.66	-0.52	+21.2%	14.20	+1.8%	-20.1%	+6.7%	+14.0%	+6.9%	+5.4%	—
Aug 13, 2025	TNS	-0.57	-0.65	-14.0%	3.13	-1.9%	-0.3%	+0.6%	+8.6%	+0.6%	+0.0%	—
May 14, 2025	TNS	-0.59	-0.53	+10.2%	2.20	+0.0%	+10.5%	+4.1%	+0.4%	+14.6%	-2.1%	—
Mar 20, 2025	TNS	-0.65	-0.56	+13.8%	2.69	-2.2%	-1.5%	+0.0%	-4.5%	-1.2%	-3.6%	—
Nov 12, 2024	TNS	-0.67	-0.62	+7.5%	4.50	+2.7%	+0.7%	+1.5%	-1.7%	+1.8%	-2.6%	—
Aug 13, 2024	TNS	-0.71	-0.60	+15.5%	8.98	+0.2%	+6.0%	-1.5%	-0.2%	+8.2%	-0.5%	—
May 14, 2024	TNS	-0.46	-0.76	-65.2%	14.16	-1.1%	-2.3%	-7.4%	-2.7%	-0.6%	+2.3%	—
Mar 21, 2024	TNS	-1.67	-7.77	-365.3%	15.15	-2.0%	+5.4%	+4.3%	+7.8%	-6.5%	-8.5%	—
Feb 5, 2024	TNS	—	-0.34	—	21.80	-4.1%	-11.1%	-2.1%	+0.0%	-12.8%	-15.8%	—
Jun 29, 2023	TNS	—	-0.32	—	—	—	—	—	—	—	—	—
Mar 31, 2023	AMC	—	-0.27	—	—	—	—	—	—	—	—	—

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
May 5	BofA Securities	Initiates	Buy	$35	$25.19	$25.91	+2.9%	+1.0%	-3.8%	-1.7%	+0.8%	+1.1%
Apr 22	Chardan Capital	Maintains	Buy → Buy	—	$25.59	$26.22	+2.5%	+6.1%	-5.3%	-4.6%	-1.0%	+0.8%
Apr 2	Wedbush	Maintains	Neutral → Neutral	—	$23.41	$20.00	-14.6%	-7.4%	+3.9%	-5.2%	+1.7%	+3.2%
Apr 2	Baird	Maintains	Outperform → Outperform	—	$23.41	$20.00	-14.6%	-7.4%	+3.9%	-5.2%	+1.7%	+3.2%
Apr 2	Chardan Capital	Maintains	Buy → Buy	—	$23.41	$20.00	-14.6%	-7.4%	+3.9%	-5.2%	+1.7%	+3.2%
Apr 2	Jones Trading	Maintains	Buy → Buy	—	$23.41	$20.00	-14.6%	-7.4%	+3.9%	-5.2%	+1.7%	+3.2%
Apr 2	HC Wainwright & Co.	Maintains	Buy → Buy	—	$23.41	$20.00	-14.6%	-7.4%	+3.9%	-5.2%	+1.7%	+3.2%
Mar 18	Baird	Maintains	Outperform → Outperform	—	$22.36	$22.66	+1.3%	+0.7%	-2.1%	-2.6%	-6.8%	+0.8%
Mar 17	Chardan Capital	Maintains	Buy → Buy	—	$24.29	$24.32	+0.1%	-7.9%	+0.7%	-2.1%	-2.6%	-6.8%
Mar 17	Wedbush	Maintains	Neutral → Neutral	—	$24.29	$24.32	+0.1%	-7.9%	+0.7%	-2.1%	-2.6%	-6.8%
Feb 17	BTIG	Maintains	Buy → Buy	—	$16.89	$16.63	-1.5%	+14.0%	-5.9%	+7.6%	-9.6%	+3.9%
Jan 5	Chardan Capital	Maintains	Buy → Buy	—	$16.59	$16.63	+0.2%	-0.4%	-8.8%	+6.1%	-0.7%	+3.0%
Nov 13	Baird	Maintains	Outperform → Outperform	—	$14.20	$14.45	+1.8%	-20.1%	+6.7%	+14.0%	+6.9%	+5.4%
Nov 12	Jefferies	Maintains	Buy → Buy	—	$13.40	$13.40	+0.0%	+6.0%	-20.1%	+6.7%	+14.0%	+6.9%
Oct 24	HC Wainwright & Co.	Maintains	Buy → Buy	—	$11.18	$11.65	+4.2%	-1.6%	+11.4%	+11.2%	+3.1%	+2.0%
Oct 20	Baird	Maintains	Outperform → Outperform	—	$6.08	$6.75	+11.0%	+80.9%	-1.4%	-6.0%	+9.6%	-1.6%
Aug 18	HC Wainwright & Co.	Maintains	Buy → Buy	—	$3.14	$3.07	-2.2%	+8.6%	+0.6%	+0.0%	+4.7%	+8.6%
Jun 26	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.57	$2.38	-7.4%	-10.5%	+0.4%	-4.8%	+0.9%	+3.6%
May 15	Wedbush	Maintains	Neutral → Neutral	—	$2.20	$2.20	+0.0%	+10.5%	+4.1%	+0.4%	+14.6%	-2.1%
Nov 13	Stifel	Maintains	Buy → Buy	—	$4.50	$4.62	+2.7%	+0.7%	+1.5%	-1.7%	+1.8%	-2.6%
Oct 23	Wedbush	Downgrade	Outperform → Neutral	—	$14.53	$5.15	-64.6%	-70.0%	-5.3%	+5.8%	-3.4%	-5.0%
Oct 23	Baird	Maintains	Outperform → Outperform	—	$14.53	$5.15	-64.6%	-70.0%	-5.3%	+5.8%	-3.4%	-5.0%
Sep 10	Wedbush	Maintains	Outperform → Outperform	—	$14.11	$14.11	+0.0%	-4.6%	-0.4%	-3.1%	+4.8%	+2.1%
Mar 25	Stifel	Maintains	Buy → Buy	—	$15.97	$16.13	+1.0%	+4.3%	+7.8%	-6.5%	-8.5%	-5.1%

Data updated apr 24, 2026 6:14pm · Source: massive.com